Study of lymphoma treatment outside the lymph nodes
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at real-world data from people with non-Hodgkin lymphoma that involves organs or tissues beyond the lymph nodes. It aims to understand how well different treatments work, so your experience can help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older.
- Have a new diagnosis of non-Hodgkin lymphoma (a type of blood cancer) that has spread to or started in organs or tissues outside the lymph nodes.
- Have already received or are receiving systemic cancer treatment (like chemo or immunotherapy).
- Have at least one tumor that can be measured on imaging or exam, and have had at least one assessment of how the treatment is working.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study enrolls adults with Hodgkin or non-Hodgkin lymphoma who plan to receive chemotherapy aimed at cure. It may help doctors better understand outcomes and how lymphoma care is managed over time.
This study follows people with newly diagnosed non-Hodgkin lymphoma to collect information about how they respond to treatment. It aims to improve understanding and care for this type of blood cancer.
This study follows people with Hodgkin or non-Hodgkin lymphoma who need strong treatment to try to cure their cancer. The goal is to learn more about how the disease and its treatment affect patients over time.
This study looks at why lymphoma happens and what factors affect how well people do. It collects information from patients diagnosed between 2007 and 2027 to better understand the disease.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This study looks for biomarkers (biological signs) in blood or tissue samples from people with diffuse large B-cell lymphoma (DLBCL) to help predict how the disease behaves and how well treatment might work. Participation involves giving extra biopsy or blood samples during routine care.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.